890839-62-0

Basic information

• Product Name: 1-(prop-2-yn-1-yloxy)-2-(trifluoromethyl)benzene
• Synonyms: 1-(prop-2-yn-1-yloxy)-2-(trifluoromethyl)benzene
• CAS NO: 890839-62-0
• Molecular Weight: 200.16
• Mol File: 890839-62-0.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 1-(prop-2-yn-1-yloxy)-2-(trifluoromethyl)benzene(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(prop-2-yn-1-yloxy)-2-(trifluoromethyl)benzene(890839-62-0)
• EPA Substance Registry System: 1-(prop-2-yn-1-yloxy)-2-(trifluoromethyl)benzene(890839-62-0)

Safety Data

• Hazardous Substances Data: 890839-62-0(Hazardous Substances Data)

Upstream product

• 2003-82-9 3-bromo-2-propyne 
• 444-30-4 2-(trifluoromethyl)phenol 
• 106-96-7 propargyl bromide 

Downstream Products

• 890839-70-0 C₁₀H₁₀F₃NO 
• 890839-64-2 1-(3-chloroprop-2-ynyloxy)-2-(trifluoromethyl)benzene 

Relevant articles and documents

Synthesis of sorafenib analogues incorporating a 1,2,3-triazole ring and cytotoxicity towards hepatocellular carcinoma cell lines

A series of 1,2,3-triazole-containing Sorafenib analogues, in which the aryl urea moiety of Sorafenib (1) was replaced with a 1,2,3-triazole ring linking a substituted phenoxy fragment, were prepared successfully via Huisgen 1,3-dipolar cycloaddition and

PYRROLO SULFONAMIDE COMPOUNDS FOR MODULATION OF ORPHAN NUCLEAR RECEPTOR RAR-RELATED ORPHAN RECEPTOR-GAMMA (RORGAMMA, NR1F3) ACTIVITY AND FOR THE TREATMENT OF CHRONIC INFLAMMATORY AND AUTOIMMUNE DISEASES

The invention provides modulators for the orphan nuclear receptor RORy and methods for treating RORy mediated diseases by administrating these novel RORy modulators to a human or a mammal in need thereof. Specifically, the present invention provides pyrrolo sulfonamide compounds of Formula (1) and the enantiomers, diastereomers, tautomers, solvates and pharmaceutically acceptable salts thereof.

Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor and uses thereof

Compounds that are antagonists of the VR1 receptor, having formula (I) [image] or a pharmaceutically acceptable salt, prodrug, or salt of a prodrug thereof, wherein A1, A2, A3, A4, R7, R8, R9, X, Y, Z, L, n, and m, are as defined herein, and are useful in disorders prevented or ameliorated by inhibiting the VR1 receptor.